Betz Stephen F.'s Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Jun 16, 2025
- Accession no.
- 0000950170-25-086804
- Filed
- Jun 16, 2025
- Trade date
- Jun 12, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.14M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Betz Stephen F.CIK 0001886575 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Common Stock | MOption exerciseAcquired | +71,525 | $1.91 | +$136,612.75 | 180,551 | Direct | |
| Jun 12, 2025 | Common Stock | MOption exerciseAcquired | +16,645 | $9.28 | +$154,465.6 | 197,196 | Direct | |
| Jun 12, 2025 | Common Stock | SSaleDisposed | −97,483 | $32.23F3 | −$3,141,877.09 | 99,713 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Common Stock | MOption exerciseDisposed | −71,525 | $0.00 | $0 | 108,514 | Direct | |
| Jun 12, 2025 | Common Stock | MOption exerciseDisposed | −16,645 | $0.00 | $0 | 58,198 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $32.23 per share. The range of sales prices on the transaction date was $31.67 to $32.65 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.